«ALMASS Neo» assay solutions
«ALMASS Neo» analytical solutions are intended for extraction of target analytes from newborns’ peripheral blood samples on standard paper test blanks and transferring them to the tandem mass spectrometry system. «ALMASS Neo» analytical solutions are intended to be used together with the «ALMASS Neo» reagent kit for determination of congenital metabolic diseases in newborns by HPLC-MS/MS method.
Neonatal screening is the newborn screening program for genetic disorders. Hereditary metabolic diseases involve the quantitative analysis of a number of markers. The procedure begins in the maternity hospital, where five drops of blood are drawn from the newborn, applying them to a special card, which is then dried. This produces a sample – a Dried Blood Spot – which will be sent for further analysis. Abnormal marker analytes will indicate metabolic disorders and allow the identification of potentially sick newborns. The panel of analytes is represented by amino acids and acylcarnitines, with adenosine also added to the expandedpanel.
Screening is not literally an «assay by which a diagnosis can be made quickly and unambiguously». Further examinations are performed by other specialists, additional tests are prescribed, etc.
PDF for download
«ALMASS Neo» Assay Solutions (for 480 tests):
- «ALMASS Neo» Flow solwent – 400 mL;
- «ALMASS Neo» Extraction solution – 160 mL.